Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression

被引:25
作者
Cassivi, SD
Liu, MY
Boehler, A
Tanswell, AK
Slutsky, AS
Keshavjee, S
机构
[1] Toronto Hosp, Div Thorac Surg, Thorac Surg Res Lab, Res Inst, Toronto, ON M5G 2C4, Canada
[2] Hosp Sick Children, Dept Paediat, MRC, Grp Lung Dev, Toronto, ON M5G 1X8, Canada
[3] Univ Toronto, Mt Sinai Hosp, Div Resp Med, Toronto, ON M5G 1X5, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/S0022-5223(99)70462-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Adenovirus-mediated gene therapy has been proposed as a potential treatment modality in lung transplantation. However, to date its utility has been limited by an inflammatory host immune response that not only limits the amount and duration of transgene expression but also obviates successful retransfection. Having previously shown that by administering triple-immunosuppression, as is routine in lung transplantation, we could increase and prolong transgene expression after initial transfection, we hypothesized that transgene expression after retransfection could also be increased and prolonged. Methods: Lewis rats underwent intratracheal adenovirus-mediated transfection with the P-galactosidase gene and were randomized to either the immunosuppression group, receiving daily cyclosporine (INN: ciclosporin), azathioprine, and methylprednisolone, or the control group (no immunosuppression). Five weeks later, rats were similarly retransfected and transgene expression and post-transfection inflammation were evaluated 1, 7, and 14 days after retransfection, Results: After retransfection, immunosuppressed rats had significantly higher levels of transgene expression (P < .001), whereas control rats had virtually no detectable levels, On histologic sections of the lungs, immunosuppressed rats had overall lesser grades of post-transfection inflammation, Conclusions: Transplant immunosuppression attenuates the severe immune response to gene transfer and permits increased, prolonged, and repeated transfection. Retransfection is now achievable in the immunosuppressed lung transplant setting to allow for chronic, repeated administration of gene therapy.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 16 条
[11]   INTRATRACHEAL GENE DELIVERY WITH ADENOVIRAL VECTOR INDUCES ELEVATED SYSTEMIC IGG AND MUCOSAL IGA ANTIBODIES TO ADENOVIRUS AND BETA-GALACTOSIDASE [J].
VANGINKEL, FW ;
LIU, CG ;
SIMECKA, JW ;
DONG, JY ;
GREENWAY, T ;
FRIZZELL, RA ;
KIYONO, H ;
MCGHEE, JR ;
PASCUAL, DW .
HUMAN GENE THERAPY, 1995, 6 (07) :895-903
[12]  
YANG Y, 1994, NAT GENET, V7, P363
[13]   CELLULAR AND HUMORAL IMMUNE-RESPONSES TO VIRAL-ANTIGENS CREATE BARRIERS TO LUNG-DIRECTED GENE-THERAPY WITH RECOMBINANT ADENOVIRUSES [J].
YANG, YP ;
LI, Q ;
ERTL, HCJ ;
WILSON, JM .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2004-2015
[14]   RECOMBINANT IL-12 PREVENTS FORMATION OF BLOCKING IGA ANTIBODIES TO RECOMBINANT ADENOVIRUS AND ALLOWS REPEATED GENE-THERAPY TO MOUSE LUNG [J].
YANG, YP ;
TRINCHIERI, G ;
WILSON, JM .
NATURE MEDICINE, 1995, 1 (09) :890-893
[15]   CELLULAR-IMMUNITY TO VIRAL-ANTIGENS LIMITS E1-DELETED ADENOVIRUSES FOR GENE-THERAPY [J].
YANG, YP ;
NUNES, FA ;
BERENCSI, K ;
FURTH, EE ;
GONCZOL, E ;
WILSON, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4407-4411
[16]  
YEI SP, 1994, GENE THER, V1, P192